ArticleCancer research2013
FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Noncoding RNA-mediated regulation of pyroptotic cell death in cancer.Frontiers in oncology · 2022Review
- Forkhead Box Protein P3 (FOXP3) Represses ATF3 Transcriptional Activity.International journal of molecular sciences · 2021Article
- Prognostic Implications of Immune-Related Genes' (IRGs) Signature Models in Cervical Cancer and Endometrial Cancer.Frontiers in genetics · 2020Article
- FOXP3 Activates SUMO-ConjugatingInternational journal of molecular sciences · 2018Article
- FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer.Molecular cancer · 2017Article
- MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer.Oncotarget · 2017Article
- BRCA1 Mutation: A Predictive Marker for Radiation Therapy?International journal of radiation oncology, biology, physics · 2015Review
- Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma.Oncoimmunology · 2015Article
- Foxp3 expression in T regulatory cells and other cell lineages.Cancer immunology, immunotherapy : CII · 2014Review
- FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.Oncotarget · 2014Article
- Bioactive compounds from the roots of Asiasarum heterotropoides.Molecules (Basel, Switzerland) · 2013Article
- IPEX Syndrome, FOXP3 and Cancer.Journal of syndromes · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
FOXP3 is an X-linked tumor suppressor gene and a master regulator in T regulatory cell function. This gene has been found to be mutated frequently in breast and prostate cancers and to inhibit tumor cell growth, but its functional significance in DNA repair has not been studied. We found that FOXP3 silencing stimulates homologous recombination-mediated DNA repair and also repair of γ-irradiation-induced DNA damage. Expression profiling and chromatin-immunoprecipitation analyses revealed that FOXP3 regulated the BRCA1-mediated DNA repair program. Among 48 FOXP3-regulated DNA repair genes, BRCA1 and 12 others were direct targets of FOXP3 transcriptional control. Site-specific interaction of FOXP3 with the BRCA1 promoter repressed its transcription. Somatic FOXP3 mutants identified in breast cancer samples had reduced BRCA1 repressor activity, whereas FOXP3 silencing and knock-in of a prostate cancer-derived somatic FOXP3 mutant increased the radioresistance of cancer cells. Together our findings provide a missing link between FOXP3 function and DNA repair programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.